Pneumatic nebulizer sales are predicted to rise at a compound annual growth rate (CAGR) of 4% globally, from a market worth of US$ 699 million in 2022 to US$ 850.4 million by 2027. Because of their advantages, which include better drug delivery and less dosage waste, sales of breath-actuated nebulizers are expected to grow at a comparable CAGR of 4% over the next five years.
A pneumatic nebulizer uses a structural device that resembles a jet to distribute compressed gas, creating a negative pressure zone. After being entrained into the gas stream, the material to be aerosolized is sheared into a liquid film. This film becomes unstable and breaks up into droplets due to surface tension forces.
ππ¨π°π§π₯π¨ππ π πππ¦π©π₯π ππ¨π©π² π¨π ππ‘π’π¬ πππ©π¨π«π: https://www.factmr.com/connectus/sample?flag=S&rep_id=7716
Which Respiratory Diseases Are Driving Pneumatic Nebulizer Sales?
The pneumatic nebulizers market is expanding due to the increasing prevalence of asthma and COPD.
In 2019, asthma resulted in 461,000 deaths globally and affected approximately 262 million people, according to the World Health Organization. Long-term treatment for COPD and asthma can lead to significant healthcare costs. Additionally, growing urbanization, poor air quality, and rising awareness of respiratory diseases and their treatments are boosting demand for pneumatic nebulizers.
For example, the OMRON Electro-pneumatic Nebulizer A3 Complete provides a wide range of nebulization options to treat various respiratory conditions, including upper and lower airway chronic diseases, respiratory infections, seasonal allergies, colds, asthma, and COPD.
How Can New Market Entrants Increase Their Revenue Share?
New players can boost revenue by investing in advanced nebulizer technologies that improve accessibility for patients and healthcare providers.
For instance, Omron Healthcare offers the OMRON MicroAIR U100, a portable device that treats various respiratory conditions, with a 360-degree operation for ease of use and mesh technology for efficient drug delivery.
Respira Technologies introduced the RespiRx nebulizer platform, a portable vibrating mesh nebulizer for treating local and systemic conditions.
As demand for portable devices grows, new entrants can expand their market share by focusing on innovation, increasing healthcare provider awareness, and leveraging collaborations.
Country-wise Analysis
The U.S. market for pneumatic nebulizers is growing rapidly due to the adoption of advanced nebulizers that offer quick drug administration and precise technical performance.
For example, Omron Healthcare launched the Portable MicroAir Nebulizer, which is compact, weighing only 6 oz, fits comfortably in the palm, and features Vibrating Mesh Technology.
Manufacturers are focusing on creating portable devices suitable for neonates with respiratory conditions like COPD and asthma, offering rechargeable batteries and various mask styles for neonatal use. These innovations are contributing to the expansion of the U.S. pneumatic nebulizer market.
Competitive Landscape
Leading companies in the pneumatic nebulizer market include Omron Corp., PARI Pharma, General Electric, Allied Healthcare, Becton Dickinson, and GF Health Products.
The market is expanding with the rise of advanced mesh nebulizers, which are now commonly used in clinical trials by pharmaceutical companies.
Additionally, small producers in emerging markets are contributing by offering cost-effective nebulizers.
Omron Healthcare introduced the OMRON NE C106 in July 2020, expanding their compressor nebulizer range and continuing innovation in respiratory medication delivery.
Comments
0 comment